[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100551989","comparison-of-two-non-invasive-neuromodulation-techniques-as-synergistic-therapy-to-cognitive-stimulation-in-amnestic-mild-cognitive-impairment-amci-100551989",false,"NCT06467253","Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI)","Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI): Genetic Characterization, Proteins Associated With Neurogenesis, Clinical, Neuroimaging and Electrophysiological Markers","Inclusion criteria:\n\n* Being vaccinated against the SARS-COV2 virus.\n* Speak Spanish fluently.\n* Level of schooling greater than or equal to 6 years.\n* Amnestic mild cognitive impairment established by clinical examination performed by the treating physician (MoCA score: 19-25 points for probable aMCI) (based on the National Institute on Aging and Alzheimer's Association (NIA\u002FAA) criteria, 2011).\n* Adequate visual and auditory acuity to perform neuropsychological tests and cognitive rehabilitation.\n* If receiving psychotropic drugs, having started the drugs at least 12 weeks before the start of the study, remaining at stable doses, or having suspended the drugs for at least 4 weeks before the study.\n* Be in good health without non-psychiatric medical diseases (uncontrolled systemic arterial hypertension, diabetes mellitus or dyslipidemia, infections, thyroid disease, vitamin deficiency) interfering with the study.\n* Willingness to participate in a study scheduled for 8 weeks and that participants can go to the Instituto Nacional De Psiquiatría for treatments, as well as scheduled evaluations.\n* An informant to respond to some of the assessment questionnaires throughout the study and who would stay with the participant for at least 10 h\u002Fweek.\n\nExclusion Criteria:\n\n* Any neurological disease that raises suspicion of cognitive failure other than Alzheimer's disease, such as Parkinson's, multi-infarct dementia, Huntington's disease, hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of trauma craniocerebral with loss of alertness.\n* Participants with a history of severe psychiatric disorders according to DSM-5 (bipolar disorder, schizophrenia, chronic depression) or with psychotic features, agitation, or behavioral problems in the last three months that could lead to difficulties in meeting the protocol.\n* History of psychoactive substance abuse and current alcohol consumption with a pattern of abuse or dependence in the last two years.\n* Participants with alterations in a conventional electroencephalogram (paroxysmal phenomena identified by a neurophysiologist).\n* Participants with pacemakers, intracranial metal objects, or history of brain surgery, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.\n* Participation in the last 6 months in a clinical study that involved neuropsychological assessment.","ALL","55 Years","85 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a comparative, double-blind, randomized controlled clinical trial for people with Amnestic Mild Cognitive Impairment. The investigators will compare the effects of two non-invasive neuromodulation techniques (Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation) combined with cognitive stimulation. These non-invasive neuromodulating techniques will be applied as a treatment alternative to be able to compare non-invasive techniques with cognitive stimulation CS alone, taking into account clinical and neuropsychological evaluations in addition to: 1) the known clinical risk factors (physical activity, comorbidities treatment, etc.) that allow the investigators to characterize the participants; 2) characterize the participants with genetic biomarkers using the APOE4, CR1, COMT, TREM2 and ABCA7 genotype; 3) document the biological effects related to neurogenesis from olfactory epithelial neural progenitor cells and solubles factors of serum; 4) use hippocampal volume, cortical thickness of the medial temporal cortex and parietal cortex by means of structural magnetic resonance imaging and the default mode network by means of functional magnetic resonance imaging at rest as a biomarker of response to treatment and 5) associate the response to treatment with changes in Motor Evoked Potential (MEP) amplitude and latency in order to generate a response-to-treatment biomarker with neuromodulators in Mild Cognitive Impairment (MCI) and changes in electroencephalogram.",[27],"Mild Cognitive Impairment",[29,30,31,32,33,34],"Mild cognitive impairment","Repetitive Transcranial Magnetic Stimulation rTMS","Transcranial Direct Current Stimulation tDCS","Neuromodulation Techniques","Amnestic Mild Cognitive Impairment","Cognitive Stimulation","RECRUITING","2024-06-19",{"date":38,"type":39},"2024-06-20","ACTUAL",{"date":41,"type":39},"2023-06-01",{"date":43,"type":21},"2027-06-15",{"name":45,"class":46},"Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100530661","effect-of-hf-rtms-on-serum-bdnf-in-cocaine-use-disorder-100530661","NCT06189690","Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder","Effects of 5-Hz Repetitive Transcranial Magnetic Stimulation on Serum Brain Derived Neurotrophic Factor and Clinical Variables in Cocaine Use Disorder","Inclusion Criteria:\n\n1. Current cocaine use disorder according to the Diagnostic and statistical manual of mental disorders (DSM 5).\n2. Cocaine crack or powder use for at least 12 months with a frequency of 3 times or more per week, with abstinence periods shorter than 1 year for the last year.\n3. Primary school completed.\n\nExclusion Criteria:\n\n1. Personal or first degree family history of any neurological disorder including, but not limited to, organic brain syndrome, epilepsy, brain injuries, multiple sclerosis, conditions that increase intracranial pressure.\n2. Personal history of brain surgery or traumatic brain injury.\n3. Comorbilities that could represent a risk of neuroinfection or increased convulsive threshoid.\n4. Other than alcohol, tobacco or marijuana substance use disorder.\n5. If the patient does not meet the safety criteria for rTMS.\n6. Current use of any medication that might provoque seizures or any anticonvulsant drugs.\n7. Personal history of schizophrenia, mania\u002Fhypomania or OCD.\n8. Personal history of myocardial infarction, angina, congestive heart failure, cerebrovascular events, transient ischemic attack or any other heart condition currently undergoing medical treatment.\n9. Personal history of seizures or detection of paroxysmal EEG activity.","18 Years","50 Years",{"count":58,"type":21},102,[24],"This study aims to explore the effect of 5-Hz rTMS over the left dorsolateral prefrontal cortex on the BDNF, craving and cognitive function. This study will be longitudinal, with a short-term double-blind placebo-controlled phase consisting of 20 rTMS sessions and a long-term phase, consisting of 2 weekly sessions for 12 weeks. Participants will be clinically assessed pre-treatment (T0), after 20-sessions phase (T1) and after 12-weeks phase (T2) by an interview about psychiatric symptoms. Also, blood will be obtained in the same T0, T1 and T2 to peripheral levels of BDNF determination. Cognitive state will be measured at the same time-points (T0, T1, T2) by paper-pencil and computerized neuropsychological assessment. Researchers will compare active rTMS versus placebo 5 Hz-rTMS on described variables. Additionally, a comparative group (without rTMS intervention) will be included to equivalently measure described variables during periods without cocaine consumption.",[62],"Cocaine Dependence",[64,65,66,67],"Craving","BDNF","rTMS","DLPFC","2023-12-19",{"date":70,"type":39},"2024-01-03",{"date":72,"type":39},"2022-01-06",{"date":74,"type":21},"2027-12-01",{"name":45,"class":46},""]